Nothing Special   »   [go: up one dir, main page]

ES2086270T3 - Metabolitos de terfenadina y sus isomeros opticamente puros para tratar trastornos alergicos. - Google Patents

Metabolitos de terfenadina y sus isomeros opticamente puros para tratar trastornos alergicos.

Info

Publication number
ES2086270T3
ES2086270T3 ES93918584T ES93918584T ES2086270T3 ES 2086270 T3 ES2086270 T3 ES 2086270T3 ES 93918584 T ES93918584 T ES 93918584T ES 93918584 T ES93918584 T ES 93918584T ES 2086270 T3 ES2086270 T3 ES 2086270T3
Authority
ES
Spain
Prior art keywords
terfenadine
metabolites
optically pure
allergic disorders
pure isomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93918584T
Other languages
English (en)
Other versions
ES2086270T5 (es
ES2086270T1 (es
Inventor
James W Young
Nancy M Gray
Raymond L Woosley
Yiwang Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Georgetown University
Original Assignee
Georgetown University
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27129882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2086270(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Georgetown University, Sepracor Inc filed Critical Georgetown University
Publication of ES2086270T1 publication Critical patent/ES2086270T1/es
Application granted granted Critical
Publication of ES2086270T3 publication Critical patent/ES2086270T3/es
Publication of ES2086270T5 publication Critical patent/ES2086270T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Epoxy Compounds (AREA)

Abstract

UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN COMPUESTO DE FORMULA (I): DONDE Z ES COOH, COOCH{SUB,3} O CH{SUB,2}OH, O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, PARA USAR EN UN TRATAMIENTO ANTIHISTAMINICO QUE NO INDUZCA UNA ARRITMIA CARDIACA SIGNIFICATIVA, QUE CONSTA DE LA ADMINISTRACION DE UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DE UN COMPUESTO DE FORMULA (I) A UN PACIENTE HUMANO.
ES93918584T 1992-08-03 1993-08-03 Metabolitos de terfenadina y sus isomeros opticamente puros para tratar trastornos alergicos. Expired - Lifetime ES2086270T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92415692A 1992-08-03 1992-08-03
US92418292A 1992-08-03 1992-08-03

Publications (3)

Publication Number Publication Date
ES2086270T1 ES2086270T1 (es) 1996-07-01
ES2086270T3 true ES2086270T3 (es) 1998-03-01
ES2086270T5 ES2086270T5 (es) 2001-02-01

Family

ID=27129882

Family Applications (3)

Application Number Title Priority Date Filing Date
ES97104837T Expired - Lifetime ES2257757T3 (es) 1992-08-03 1993-08-03 Carboxilato de terfenadina y el tratamiento de trastornos alergicos.
ES93918584T Expired - Lifetime ES2086270T5 (es) 1992-08-03 1993-08-03 Metabolitos de terfenadina y sus isomeros opticamente puros para tratar trastornos alergicos.
ES02006356T Expired - Lifetime ES2284740T3 (es) 1992-08-03 1993-08-03 Carboxilato de terfenadina y el tratamiento de la irritacion cutanea.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES97104837T Expired - Lifetime ES2257757T3 (es) 1992-08-03 1993-08-03 Carboxilato de terfenadina y el tratamiento de trastornos alergicos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES02006356T Expired - Lifetime ES2284740T3 (es) 1992-08-03 1993-08-03 Carboxilato de terfenadina y el tratamiento de la irritacion cutanea.

Country Status (24)

Country Link
US (1) US5375693A (es)
EP (4) EP1688142A1 (es)
JP (6) JP3041954B2 (es)
KR (1) KR950702420A (es)
AT (3) ATE363283T1 (es)
AU (3) AU675240B2 (es)
BR (1) BR9306841A (es)
CA (1) CA2141572C (es)
CZ (1) CZ27495A3 (es)
DE (5) DE69334008T2 (es)
DK (3) DK0815860T3 (es)
ES (3) ES2257757T3 (es)
FI (1) FI950467A (es)
GB (1) GB2284351B (es)
GR (3) GR960300024T1 (es)
HK (1) HK1045806B (es)
HU (1) HU226242B1 (es)
NO (1) NO310644B1 (es)
PL (1) PL174373B1 (es)
PT (2) PT815860E (es)
RO (1) RO116043B1 (es)
RU (1) RU2167657C2 (es)
SK (1) SK12495A3 (es)
WO (1) WO1994003170A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR950701525A (ko) * 1992-05-11 1995-04-28 스티븐 엘. 네스비트 간 손상 환자의 항히스타민제로서의 테르페나딘 유도체의 용도(Use of Terfenadine Derivatives as Antihistaminics in a Hepatically Impaired Patient)
DK0815860T3 (da) 1992-08-03 2006-08-14 Sepracor Inc Terfenadincarboxylat og behandlingen af allergiske lidelser
KR100387347B1 (ko) * 1993-06-24 2003-11-28 알바니 몰레큘라 리써치, 인크. 피페리딘 유도체 및 그의 제조 방법
US20020007068A1 (en) 1999-07-16 2002-01-17 D'ambra Thomas E. Piperidine derivatives and process for their production
WO1995010278A1 (en) * 1993-10-15 1995-04-20 Hoechst Marion Roussel, Inc. Treatment of allergic disorders with terfenadine carboxylate
AU693892B2 (en) 1994-05-18 1998-07-09 Aventisub Ii Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof
US20030045722A1 (en) * 1994-05-18 2003-03-06 Henton Daniel R. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
US5455049A (en) * 1995-01-04 1995-10-03 Ascent Pharmaceuticals, Inc. Terfenadine oral powder
WO1996026726A1 (en) * 1995-02-28 1996-09-06 Hoechst Marion Roussel, Inc. Pharmaceutical composition for piperidinoalkanol compounds
GB9513972D0 (en) * 1995-07-08 1995-09-06 Merck Sharp & Dohme Pharmaceutical compositions
US5906747A (en) * 1995-11-13 1999-05-25 Biosepra Inc. Separation of molecules from dilute solutions using composite chromatography media having high dynamic sorptive capacity at high flow rates
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6355656B1 (en) 1995-12-04 2002-03-12 Celgene Corporation Phenidate drug formulations having diminished abuse potential
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US5908850A (en) * 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
US5733756A (en) * 1996-01-05 1998-03-31 Celgene Corporation Lactams and processes for stereoselective enrichment of lactams, amides, and esters
US6201124B1 (en) 1995-12-21 2001-03-13 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US6153754A (en) 1995-12-21 2000-11-28 Albany Molecular Research, Inc. Process for production of piperidine derivatives
ES2124167B1 (es) * 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
US5925761A (en) * 1997-02-04 1999-07-20 Sepracor Inc. Synthesis of terfenadine and derivatives
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
EP0998272B1 (en) * 1997-08-26 2003-05-02 Aventis Pharmaceuticals Inc. Pharmaceutical composition for combination of piperidinoalkanol-decongestant
US6194431B1 (en) 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
DE19913862C2 (de) * 1999-03-26 2003-04-10 Forschungszentrum Juelich Gmbh Verfahren zur biokatalysierten Umsetzung schlecht wasserlöslicher Substanzen
DE10007203A1 (de) * 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
US6613907B2 (en) 2000-11-08 2003-09-02 Amr Technology, Inc. Process for the production of piperidine derivatives with microorganisms
US20030021849A1 (en) * 2001-04-09 2003-01-30 Ben-Zion Dolitzky Polymorphs of fexofenadine hydrochloride
HUP0400299A2 (en) * 2001-04-09 2007-08-28 Teva Pharma Polymorphs of fexofenadine hydrochloride
WO2003020274A1 (en) * 2001-08-30 2003-03-13 Aventis Pharmaceuticals Inc. Treatment of atopic dermatitis
EP1474392A1 (en) * 2002-06-10 2004-11-10 Teva Pharmaceutical Industries Ltd. Polymorphic form xvi of fexofenadine hydrochloride
US20050026890A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
JP4515121B2 (ja) 2004-03-15 2010-07-28 東芝テック株式会社 ワイヤドットプリンタヘッド及びワイヤドットプリンタ
JP4473021B2 (ja) 2004-03-22 2010-06-02 東芝テック株式会社 窒化層形成方法、磁気回路形成部材、アーマチュア、ワイヤドットプリンタヘッド及びワイヤドットプリンタ
US20050256163A1 (en) * 2004-04-26 2005-11-17 Ilan Kor Crystalline forms of fexofenadine hydrochloride and processes for their preparation
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
US7498443B2 (en) 2004-09-17 2009-03-03 Albany Molecular Research, Inc. Process for production of carebastine
US7498345B2 (en) 2004-09-17 2009-03-03 Albany Molecular Research, Inc. Process for production of piperidine derivatives
JP2008514641A (ja) * 2004-09-28 2008-05-08 テバ ファーマシューティカル インダストリーズ リミティド 結晶形フェキソフェナジン、およびその調製方法
KR20070087643A (ko) * 2004-12-09 2007-08-28 셀진 코포레이션 Ｄ-트레오 메틸페니데이트를 이용한 치료
MX2008006076A (es) 2005-11-09 2008-12-16 Combinatorx Inc Metodos, composiciones y kits para el tratamiento de condiciones medicas.
EP2139325B1 (en) * 2007-04-13 2015-01-14 Southern Research Institute Bithionol as anti-angiogenic agent
US20090076080A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched fexofenadine
US20150238473A1 (en) * 2012-09-27 2015-08-27 University Of Rochester Methods and compositions for treating infection
WO2016154028A1 (en) * 2015-03-26 2016-09-29 Iversen Jacqueline M Methods and compositions to inhibit symptoms associated with veisalgia
DE102017130361A1 (de) 2017-12-18 2019-07-04 Lsp Innovative Automotive Systems Gmbh Statorzahn und Stator mit guter elektrischer Isolierung und gleichzeitig sehr hoher Wärmeleitfähigkeit zur Leistungssteigerung von Elektromotoren

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US880801A (en) † 1908-03-03 Harold Larsen Vibrator.
US922890A (en) † 1907-03-26 1909-05-25 Peder Joergen Hansen Stream-motor.
US4254129A (en) † 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4552899A (en) † 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4829064A (en) † 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4996061A (en) † 1987-10-07 1991-02-26 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol-decongestant combination
US4929605A (en) * 1987-10-07 1990-05-29 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol derivatives
HU226561B1 (en) * 1992-04-10 2009-04-28 Merrell Dow Pharma Process for preparation 4-diphenylmethyl piperidine derivatives and the novel intermediates thereof
KR950701525A (ko) 1992-05-11 1995-04-28 스티븐 엘. 네스비트 간 손상 환자의 항히스타민제로서의 테르페나딘 유도체의 용도(Use of Terfenadine Derivatives as Antihistaminics in a Hepatically Impaired Patient)
DK0815860T3 (da) 1992-08-03 2006-08-14 Sepracor Inc Terfenadincarboxylat og behandlingen af allergiske lidelser
KR100387347B1 (ko) * 1993-06-24 2003-11-28 알바니 몰레큘라 리써치, 인크. 피페리딘 유도체 및 그의 제조 방법
CN1159277C (zh) * 1993-06-25 2004-07-28 默里尔药物公司 用于制备抗组胺哌啶衍生物的新中间体
CA2128820A1 (en) * 1993-07-27 1995-01-28 Walter G. Gowan, Jr. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
CA2128821A1 (en) * 1993-07-27 1995-01-28 Dilip J. Gole Freeze-dried pharmaceutical dosage form and process for separation thereof
WO1995010278A1 (en) * 1993-10-15 1995-04-20 Hoechst Marion Roussel, Inc. Treatment of allergic disorders with terfenadine carboxylate

Also Published As

Publication number Publication date
DE69334008D1 (de) 2006-05-24
JP3037697B2 (ja) 2000-04-24
PL307339A1 (en) 1995-05-15
DE9320925U1 (de) 1995-08-31
KR950702420A (ko) 1995-07-29
JP3288660B2 (ja) 2002-06-04
JP2000086512A (ja) 2000-03-28
GR3026530T3 (en) 1998-07-31
EP1214937B1 (en) 2007-05-30
HUT71889A (en) 1996-02-28
RU2167657C2 (ru) 2001-05-27
DK0701443T4 (da) 2000-12-18
JP3288662B2 (ja) 2002-06-04
JPH08500348A (ja) 1996-01-16
DE701443T1 (de) 1997-01-30
FI950467A0 (fi) 1995-02-02
ATE363283T1 (de) 2007-06-15
JP2000086513A (ja) 2000-03-28
DK1214937T3 (da) 2007-09-17
RU95107881A (ru) 1996-11-27
GB2284351B (en) 1996-11-27
ES2086270T5 (es) 2001-02-01
NO950374D0 (no) 1995-02-01
EP0815860A3 (en) 1998-01-14
AU1842999A (en) 1999-04-29
RO116043B1 (ro) 2000-10-30
EP1214937A2 (en) 2002-06-19
GR960300024T1 (en) 1996-05-31
FI950467A (fi) 1995-03-31
GR3035417T3 (en) 2001-05-31
SK12495A3 (en) 1997-01-08
JP3041954B2 (ja) 2000-05-15
CA2141572A1 (en) 1994-02-17
EP0701443B1 (en) 1998-01-21
EP1214937A3 (en) 2002-10-30
DE69334145T2 (de) 2008-01-24
PT815860E (pt) 2006-08-31
EP0815860B1 (en) 2006-04-12
AU4798693A (en) 1994-03-03
EP1688142A1 (en) 2006-08-09
DE69316660T2 (de) 1998-05-07
JP2000086514A (ja) 2000-03-28
DE69316660D1 (de) 1998-02-26
EP0701443A1 (en) 1996-03-20
DK0701443T3 (da) 1998-02-09
GB2284351A (en) 1995-06-07
PT1214937E (pt) 2007-07-25
US5375693A (en) 1994-12-27
JP3288661B2 (ja) 2002-06-04
BR9306841A (pt) 1998-12-08
EP0701443B2 (en) 2000-11-22
CZ27495A3 (en) 1996-09-11
ES2086270T1 (es) 1996-07-01
WO1994003170A1 (en) 1994-02-17
ES2257757T3 (es) 2006-08-01
HK1045806A1 (en) 2002-12-13
ES2284740T3 (es) 2007-11-16
NO310644B1 (no) 2001-08-06
HU226242B1 (en) 2008-07-28
HU9500313D0 (en) 1995-03-28
ATE162399T1 (de) 1998-02-15
DK0815860T3 (da) 2006-08-14
JP2000086515A (ja) 2000-03-28
DE69316660T3 (de) 2001-04-05
HK1045806B (zh) 2008-03-14
DE69334008T2 (de) 2006-10-19
CA2141572C (en) 2001-02-06
ATE322899T1 (de) 2006-04-15
AU675240B2 (en) 1997-01-30
AU7182296A (en) 1997-01-30
PL174373B1 (pl) 1998-07-31
NO950374L (no) 1995-03-29
EP0815860A2 (en) 1998-01-07
DE69334145D1 (de) 2007-07-12
JP2000086516A (ja) 2000-03-28
GB9502183D0 (en) 1995-03-22

Similar Documents

Publication Publication Date Title
ES2086270T3 (es) Metabolitos de terfenadina y sus isomeros opticamente puros para tratar trastornos alergicos.
ATE158182T1 (de) Arzneimittel sowie deren herstellung und deren verwendung bei der bekämpfung von schmerzen und/oder entzündungen an tieren und menschen
PT920865E (pt) Utilizacao de ""norastemizole"" para o tratamento de disturbios alergicos
YU49215B (sh) Primena flupirtina za dobijanje medikamenta za tretman neurodegenerativnih oboljenja

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 701443

Country of ref document: ES